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Purpose: The prognostic and predictive value of pretreatment serum levels of car-
cinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were 
assessed in advanced non-small cell lung cancer (NSCLC) patients treated with 
gefitinib or erlotinib. Materials and Methods: Pretreatment CEA and CYFRA 
21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlo-
tinib. High CEA levels (h-CEA) were significantly associated with females, pa-
tients with adenocarcinoma, and non-smokers. Results: Low CYFRA 21-1 levels 
(l-CYFRA) were significantly associated with a good performance status (ECOG 
PS 0-1). The overall response rate (RR) was 27.6%, and higher RR was associated 
with adenocarcinoma, h-CEA, and epidermal growth factor receptor (EGFR) mu-
tation. Patients with h-CEA had significantly longer progression-free survival 
(PFS) (p=0.021). Patients with l-CYFRA had significantly longer PFS and overall 
survival (p=0.006 and p<0.001, respectively). Of note, h-CEA and l-CYFRA had 
good prognosis in patients with unknown EGFR mutation status or patients with 
squamous cell carcinoma (p=0.021 and p=0.015, respectively). A good ECOG PS 
(HR=0.45, p=0.017), h-CEA (HR=0.41, p=0.007), l-CYFRA 21-1 (HR=0.52, 
p=0.025), and an EGFR mutation (HR=0.22, p<0.001) were independently predic-
tive of a longer PFS. Conclusion: h-CEA and l-CYFRA 21-1 may be prognostic 
and predictive serum markers for higher response and longer survival in patients 
with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with 
unknown EGFR mutation status or patients with squamous cell carcinoma.
Key Words:   Carcinoma, non-small-cell lung, biological markers, carcinoembry-
onic antigen, CYFRA 21-1, tyrosine kinase inhibitor
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality in the world. Non-
small cell lung cancer (NSCLC) accounts for approximately 85% of all lung can-
cer patients.1 The oral small molecule epidermal growth factor receptor (EGFR) 
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CYFRA 21-1 (normal range, 0-3.3 ng/mL) were measured 
by using a chemiluminescense enzyme immunoassay kit 
(Beckman Coulter, Inc., Brea, CA, USA) and an electro-
chemiluminescense immunoassay on an automatic analyzer 
(Elecsys 200; Roche Diagnostics Corp, Indianapolis, IN, 
USA), respectively, before TKI treatment. Histological anal-
ysis of tumors was based on the WHO classification for cell 
types.14 The clinical response to the drug was defined ac-
cording to the response evaluation criteria of RECIST 1.0 
for patients with measurable disease.15 Nucleotide sequenc-
ing of the kinase domain of EGFR (exons 18 to 21) was 
performed using nested polymerase chain reaction amplifi-
cation of individual exons. Details of sequencing have been 
described previously.16 This study was approved by the in-
stitutional review board of the Yonsei University Health 
System (Approval No. 4-2009-0700).
Statistical methods
The association between pretreatment levels of CEA and 
CYFRA 21-1 and other categorical clinical variables were 
compared using Pearson’s chi-squared test. Progression-
free survival (PFS) was defined as the time from the start 
day of TKI treatment until the date of tumor progression or 
death. Overall survival (OS) was measured from the date of 
diagnosis to the date of death or final follow-up. The sur-
vival data were estimated using a Kaplan-Meier curve and 
compared using the log-rank test. Multivariate analyses were 
performed to find prognostic markers using Cox’s propor-
tional hazards model. A p-value of less than 0.05 was con-





Four hundred fifty one patients were treated with erlotinib 
or gefitinib in Yonsei University Health System from Janu-
ary 2006 to December 2008, and 123 patients had mea-
sured pretreatment levels of CEA and CYFRA 21-1 and 
were included in this study. The clinicopathological charac-
teristics of 123 patients are summarized in Table 1. Notably, 
a high serum CEA level (≥5 ng/mL) was observed in 70 pa-
tients (56.9%), and was significantly more frequent in fe-
males, patients with adenocarcinoma, and patients without 
a history of smoking. On the other hand, 64 patients (52%) 
had an elevated serum CYFRA 21-1 level (≥3.3 ng/mL), 
which was significantly more frequent in patients with a 
tyrosine kinase inhibitors (TKIs) such as gefitinib and erlo-
tinib active responses in 10-18% of patients who failed on 
prior chemotherapy. Erlotinib has a 2-month median sur-
vival advantage over placebo,2 and gefitinib is not inferior 
compared with docetaxel.3
Treatment with EGFR TKI is effective in women, Asians, 
non-smokers, and patients with adenocarcinoma. An EGFR 
mutation was found to be the most important predictive 
factor for a response to an EGFR TKI.4 However, acquiring 
adequate tissue for EGFR mutational analysis is often not 
feasible, particularly in patients with advanced disease.2-4 
Therefore, the identification of clinical parameters that can 
serve as surrogates for EGFR mutation may prove useful 
when mutational analysis is not feasible. A recent study re-
ported that the molecular analysis of circulating tumor cells 
(CTCs) from the peripheral blood of patients with lung can-
cer was useful in monitoring changes in epithelial tumor 
genotypes during the course of treatment.5 However, this 
molecular analysis could prove to be difficult as a specific 
microfluidic-based device called the CTC chip is required.
A marker that is easily analyzed and predicts responses to 
EGFR TKI treatment is needed. Some serum markers have 
been considered potentially prognostic and predictive in 
NSCLC. Among these NSCLC markers, carcinoembryonic 
antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-
1) have been considered sensitive and valuable tumor mark-
ers for diagnosis, prognosis, and therapy monitoring.6-10 Ac-
cording to recent reports, CEA and CYFRA 21-1 were 
significant predictors of sensitivity and survival in patients 
treated with gefitinib.11-13 Therefore, we investigated the 
clinical significance of the pretreatment serum levels of 
CEA and CYFRA 21-1 in advanced NSCLC patients who 
were treated with gefitinib or erlotinib.
MATERIALS AND METHODS
　　　
We retrospectively collected clinical data on NSCLC pa-
tients who had measured pretreatment levels of CEA and 
CYFRA 21-1 and received gefitinib or erlotinib in the Sev-
erance Hospital, Yonsei University Health System, Seoul, 
Korea, from January 2006 to December 2008. Variables 
used in the pretreatment analysis were age, gender, clinical 
stage, Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS), histological type, smoking history, 
number of prior chemotherapy regimens, and EGFR muta-
tion if possible. Serum CEA (normal range, 0-5 ng/mL) and 
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and high serum CEA levels (≥5 ng/mL). The disease con-
trol rate in the patients with high CEA levels was signifi-
cantly higher than that with low CEA levels (75% vs. 
51.9%, p=0.034). There were no differences in the response 
rates according to gender, smoking history, or the number 
of prior chemotherapy regimen. There was a trend towards 
a better response rate in patients with low CYFRA 21-1 lev-
els (p=0.104). To evaluate whether the combination of CEA 
and CYFRA 21-1 levels improved the prediction accuracy, 
patients were divided into three groups according to their 
CEA and CYFRA 21-1 levels. Patients with a low CEA and 
a high CYFRA 21-1 level were defined as group A (CEA 
<5 ng/mL and CYFRA 21-1 ≥3.3 ng/mL, n=24), while 
those with both low or high CEA and CYFRA 21-1 levels 
were labeled group B (CEA <5 ng/mL and CYFR 21-1 
poor ECOG PS (p=0.017) and in those with a history of 
smoking (p=0.072). There was no difference in either CEA 
or CYFRA 21-1 levels in terms of EGFR mutation status.  
Association of serum markers with responses to EGFR 
TKIs
The median follow-up duration was 9.0 months (range, 0.2-
43 months). The median PFS was 5.0 months [95% confi-
dential interval (CI) 3.3-6.7 months], and the median OS 
was 16.0 months (95% CI, 8.7-23.3 months). Response 
was not assessable in 7 patients; four patients died and three 
patients refused treatment before response evaluation. Thir-
ty-two of the evaluable 116 patients (27.6%) showed partial 
responses. The response rate to EGFR TKIs was significantly 
higher in patients with adenocarcinoma, an EGFR mutation, 
Table 1. Comparison of Pretreatment Clinicopathological Characteristics according to CEA and CYFRA 21-1 Levels
Patient characteristics n (%)
CEA, n (%) CYFRA 21-1, n (%)
<5 ng/mL ≥5 ng/mL p value <3.3 ng/mL ≥3.3 ng/mL p value
Total 123 (100)   53 (43.1)    70 (56.9) 59 (48)   64 (52)
Age (yrs)
Median (range)   60 (34-88) 0.232 0.323
    <60 61 (49.6)   23 (37.7)    38 (62.3)    32 (52.5)    29 (47.5)
    ≥60 62 (50.4)   30 (48.4)    32 (51.6)    27 (43.5)    35 (56.5)
Sex <0 .001 0.192
    Male 70 (56.9)   40 (57.2)    30 (42.9)    30 (42.9)    40 (57.1)
    Female 53 (43.1)   13 (24.5)    40 (75.5)    29 (54.7)    24 (45.3)
Histologic type 0.043 0.995
    Adenocarcinoma 73 (59.3)   26 (35.6)    47 (64.4)    35 (47.9)    38 (52.1)
    Non-adenocarcinoma 50 (40.7) 27 (54) 23 (46) 24 (48) 52 (52)
Clinical stage 0.439 0.628
    IIIB 35 (18.5)   17 (48.6)   18 (51.4)    18 (51.4)    17 (48.6)
    IV 88 (71.5)   36 (40.9)   52 (59.1)    41 (46.6)    47 (53.4)
Performance status 0.1 0.017
    0-1 83 (67.5)   40 (48.2)   43 (51.8)    46 (55.4)    37 (44.6)
    2 40 (32.5)   13 (32.5)   27 (67.5)    13 (32.5)    27 (67.5)
Smoking history 0.036 0.072
    None 59 (47.5)   19 (32.8)   39 (67.2)    33 (56.9)    25 (43.1)
    Current+former 64 (52.5)   33 (51.6)   31 (48.2)    26 (40.6)    38 (59.4)
No. of prior regimens 0.631 0.485
    ≤1 40 (32.5) 16 (40) 24 (60)    21 (52.5)    19 (47.5)
    ≥2 83 (67.5)    37 (44.6)    46 (55.4)    38 (45.8)    45 (54.2)
TKI 0.669 0.203
    Gefitinib 72 (58.5)   29 (40.3)    43 (61.4)    37 (51.4)    35 (48.6)
    Erlotinib 51 (41.5)   24 (47.1)    27 (52.9)    22 (43.1)    29 (56.9)
EGFR mutation 0.418 0.789
    Negative 47 (38.2)   19 (40.4)    28 (59.6)    23 (48.9)    24 (51.1)
    Positive 37 (30.1)   14 (37.8)    23 (62.2)    19 (51.4)   18 (48.6)
    Unknown 39 (31.7)   20 (51.3)    19 (48.7)    17 (43.6)   22 (56.4)
CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor.  
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CYFRA 21-1 levels (8.1 months vs. 3.0 months, p=0.006). 
When sub-grouped by combined CEA and CYFRA 21-1 
levels, the three groups showed significantly different PFS, 
and group C showed the longest PFS among the three groups 
(15.0 months vs. 4.0 months vs. 2.0 months, p<0.001, for 
groups C, B, and A, respectively) (Fig. 1). Especially, group 
C also had the longest PFS in patients with squamous cell 
carcinoma (Fig. 2). In addition, high CEA and low CYFRA 
21-1 levels were a significant prognostic marker not only in 
patients with EGFR-mutant tumors, but also in patients with 
unknown EGFR-mutation status (Fig. 3). Finally, univariate 
analysis revealed several significant factors for PFS, includ-
ing good ECOG PS (6.1 months vs. 3.0 months, p=0.016) 
<3.3 ng/mL, or CEA ≥5 ng/mL and CYFR 21-1 ≥3.3 ng/
mL, n=66). Finally, patients with high CEA and low CY-
FRA 21-1 levels were defined as group C (CEA ≥5 ng/mL 
and CYFRA 21-1 <3.3 ng/mL, n=26). The three groups 
showed significantly different response rates, with the best 
responses in group C (42.3% vs. 25.8% vs. 16.7%, 
p=0.005, for groups C, B, and A, respectively) (Table 2).
Association of serum markers with survival
Patients with high CEA levels had significantly better PFS 
than those with low CEA levels (7.0 months vs. 4.0 months, 
p=0.021). In contrast, patients with low CYFRA 21-1 lev-
els also had significantly better PFS than those with high 
Table 2. Comparison of Pretreatment Clinicopathological Characteristics according to EGFR TKI Responses
Patient characteristics PR, n (%) SD, n (%) PD, n (%) p value
Total (n=116)    32 (27.6)    43 (37.1)    41 (35.3)
Age (yrs) 0.663
    <65    20 (25.6)    31 (39.8)    27 (34.6)
    ≥65    12 (31.6)    12 (31.6)    14 (36.8)
Sex 0.371
    Male    16 (24.2)    28 (42.4)    22 (33.4)
    Female 16 (32) 15 (30) 19 (38)
Histologic type 0.009
    Adenocarcinoma    25 (35.2)    19 (26.8) 27 (38)
    Non-adenocarcinoma      7 (15.6)    24 (53.3)    14 (31.1)
Performance status 0.07
    0-1    26 (32.9) 30 (38)    23 (29.1)
    2      6 (16.2)    13 (35.2)    18 (48.6)
Smoking history 0.673
    None    17 (30.9)    18 (32.7)    20 (36.4)
    Current+former 15 (25) 24 (40) 21 (35)
No. of prior regimens 0.436
    ≤1    13 (35.1)    13 (35.1)    11 (29.8)
    ≥2    19 (24.1) 30 (38) 30 (38)
Serum CEA level (ng/mL) 0.034
    <5    11 (21.1)    16 (30.8)    25 (48.1)
    ≥5    21 (32.8)    27 (42.2)    16 (25.0)
Serum CYFRA 21-1 level (ng/mL) 0.104
    <3.3    18 (32.7)    23 (41.8)    14 (25.5)
    ≥3.3 14 (23)    20 (32.8)    27 (44.2)
Combination of CEA and CYFRA 21-1 (ng/mL) 0.005
    Group C: CEA ≥5 and CYFRA 21-1 <3.3    11 (42.3)    12 (46.2)      3 (11.5)
    Group B: CEA <5 and CYFRA 21-1 <3.3 or 
      CEA ≥5 and CYFRA 21-1 ≥3.3
   17 (25.8)    26 (39.4)    23 (34.8)
    Group A: CEA <5 and CYFRA 21-1 ≥3.3      4 (16.7)      5 (20.8)    15 (62.5)
EGFR mutation (n=84) <0.001
    Negative      7 (15.6)    12 (26.7)    26 (57.8)
    Positive    18 (52.9)    10 (29.4)      6 (17.6)
PR, partial remission; SD, stable disease; PD, progression of disease; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; TKI, tyrosine 
kinase inhibitor;  EGFR, epidermal growth factor receptor.
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status (ECOG PS, 29.6 months vs. 6.1 months, p<0.001; 
EGFR mutation status, 22.0 months vs. 7.1 months, p=0.038, 
respectively). However, OS was not different by pretreat-
ment CEA levels. Patients with low CYFRA 21-1 levels 
had a longer OS than those with high CYFRA 21-1 levels 
and positive EGFR mutation status (11.0 months vs. 2.0 
months, p<0.001) (Table 3). 
Patients with good ECOG PS and a positive EGFR mu-
tation status also had significantly longer OS than those 
who had a poor ECOG PS and a negative EGFR mutation 
Fig. 1. Progression-free survival curves according to pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-
1). (A) CEA. (B) CYFRA 21-1. (C) Combinations of CEA and CYFRA 21-1 by group: a, patients with a low level of CEA and a high level of CYFRA 21-1; b, patients 
with both low or high level of CEA and CYFRA 21-1; and c, patients with a high level of CEA and a low level of CYFRA 21-1. PFS, progression-free survival.
Fig. 3. Progression-free survival curves according to pretreatment serum levels of combination of carcinoembryonic antigen (CEA) and cytokeratin-19 frag-
ments (CYFRA 21-1) by epidermal growth factor receptor (EGFR) mutation status; a, patients with a low level of CEA and a high level of CYFRA 21-1; b, pa-
tients with both low or high level of CEA and CYFRA 21-1; and c, patients with a high level of CEA and a low level of CYFRA 21-1. (A) Patients with negative 
EGFR mutation, (B) in patients with positive EGFR mutation, (C) in patients with unknown EGFR mutation status. PFS, progression-free survival.
Fig. 2. Progression-free survival curves according to pretreatment serum levels of combination of carcinoembryonic antigen (CEA) and cytokeratin-19 frag-
ments (CYFRA 21-1) by histologic difference. a, Patients with a low level of CEA and a high level of CYFRA 21-1; b, patients with both low or high level of CEA 
and CYFRA 21-1; and c, patients with a high level of CEA and a low level of CYFRA 21-1 (A) patients with adenocarcinoma, (B) in patients with squamous cell 
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CYFRA 21-1 levels, but not high CEA levels (Table 4). 
DISCUSSION
Detection of mutation in the EGFR gene in NSCLC pa-
tients treated with EGFR TKI is the most important factor 
for the prediction of a good response to these drugs.4 How-
ever, the detection of an EGFR mutation is difficult due to 
(not reached vs. 8.0 months, p<0.001). Patients in group C 
also had the longest OS among the three groups (Table 4, 
Fig. 4).   
Multivariate analysis using a Cox proportional hazards 
model indicated that a good ECOG PS, positive EGFR mu-
tation status, high pretreatment CEA levels, and low pretreat-
ment CYFRA 21-1 levels were independent predictive fac-
tors for PFS. Meanwhile, predictive factors for OS included a 
good ECOG PS, positive EGFR mutation status, and low 





95% CI p value
Median 
(months)
95% CI p value
Total 5.0 3.3-6.7 16.0  8.7-23.3
Age 0.982 0.843
    <65 4.1 2.0-6.2 15.1 10.5-19.7
    ≥65 5.6 2.8-8.4 22.0   5.5-38.5
Sex 0.985 0.902
    Male 4.1 2.7-5.6 15.1  9.3-20.9
    Female 6.0   2.5-9.50 18.1  5.7-30.6
Histologic type 0.942 0.716
    Adenocarcinoma 5.6 3.3-7.8 18.1  0.0-36.3
    Non adenocarcinoma 4.1 1.2-7.0 16.0  8.3-23.7
Performance status 0.016 <0.001
    0-1 6.1 3.2-9.0 29.6 19.9-39.4
    2 3.0 1.0-5.0   6.1  1.7-10.6
Smoking history 0.331 0.78
    None 5.0 2.8-7.2 16.0  7.0-25.0
    Current+former 4.9 3.1-6.7 14.1  1.7-26.5
No. of prior regimens 0.176 0.447
    0-1 8.1   3.2-13.0 29.6  3.3-55.3
    ≥ 2 4.0 2.0-6.0 15.0  9.1-20.9
TKI 0.679 0.935
    Gefitinib 5.6 3.6-7.5 16.0  8.9-23.1
    Erlotinib 3.9 1.5-6.3 24.0 13.2-34.9
Serum CEA level (ng/mL) 0.021 0.505
    <5 4.0 1.7-6.3 14.0  2.2-25.8
    ≥5 7.0   2.5-11.5 18.0 10.3-25.7
Serum CYFRA 21-1 level (ng/mL) 0.006 <0.001
    <3.3 8.1   2.9-13.3 NR -
    ≥3.3 3.0 2.0-4.0   8.0  5.2-10.8
Combination of CEA and CYFRA 21-1 (ng/mL) <0.001 0.002
    CEA ≥5 and CYPRA 21-1 <3.3 15.0   5.7-24.3 NR -
    CEA <5 and CYPRA 21-1 <3.3 or
      CEA ≥5 and CYPRA 21-1 ≥3.3
4.0 3.1-4.9 14.1  5.0-23.2
    CEA <5 and CYPRA 21-1 >3.3 2.0 0.9-3.1   8.0  4.8-11.2
EGFR mutation (n=84) <0.001 0.038
    Negative 2.0 1.4-2.7   7.1  3.9-10.3
    Positive 11.0   5.3-16.7 22.0 13.1-31.0
PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; 
NR,  not reached; EGFR, epidermal growth factor receptor; CI, confidential interval.
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On the contrary, Okamoto, et al.11 reported that patients 
treated with EGFR TKI with high pretreatment levels of 
CEA had a longer survival and a better response than those 
with low CEA levels. They attributed this to a possible anti-
apoptotic signal of the mutant EGFR pathway that may ele-
vate the expression level of CEA protein. Our data are simi-
lar to the data of Okamoto, et al.11 Shoji, et al.22 reported 
that the rate of EGFR gene mutation is significantly in-
creased as the serum CEA level increases (for serum CEA 
levels of <5, ≥5 but <20, and ≥20 the rate of EGFR gene 
mutation was 35%, 55%, and 87.5%, respectively; p=0.040). 
However, our data showed that the status of EGFR muta-
tion made no difference in the CEA levels. According to 
the limited amount of available tissue.2-4 Therefore, another 
biomarker that can improve the prediction of response to 
these targeted drugs is needed.
CEA was first described by Gold and Freedman17 in 1965 
as an antigen expressed by gastrointestinal carcinoma cells. 
Although CEA was often falsely elevated in smokers and in 
patients with restrictive or obstructive pulmonary disease,18-20 
abnormally elevated CEA levels were reported in 30-70% 
of patients with NSCLC and were most frequently observed 
in patients with adenocarcinoma and advanced stage carci-
noma.21 In addition, several studies have shown that high 
CEA levels were a potential marker of poor prognosis in 
NSCLC regardless of treatment.7,21
Table 4. Multivariate Predictions of Survival
Category
PFS OS
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Age
    <65 vs. ≥65   1.23 0.67-2.28   0.506   1.18 0.64-2.29 0.633
Sex
    Female vs. Male   2.86   0.75-10.89   0.124   1.24 0.27-6.75 0.808
Histologic type
    Non-adeno vs. Adeno 0.8 0.41-1.56   0.521   1.59 0.81-3.14 0.182
Clinical stage
    IV vs. III   0.64 0.35-1.15   0.134 0.8 0.40-1.60 0.534
Performance status
    0-1 vs. 2   2.02 1.13-3.61   0.017   2.13 1.14-3.98 0.018
Smoking history
    None vs. Current+former   1.48 0.39-5.56 0.57   1.38 0.25-7.61 0.706
Serum CEA level (ng/mL)
    <5 vs. ≥5   0.41 0.24-0.78   0.007   0.55 0.25-1.21 0.554
Serum CYFRA 21-1 level (ng/mL)
    <3.3 vs. ≥3.3   1.93 1.09-3.44   0.025   2.76 1.38-5.53 0.004
EGFR mutation (n=84)
   Negative vs. Positive   0.22 0.11-0.42 <0.001   0.53   0.28-1.004 0.051
PFS, progression-free survival; OS, overall survival; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; EGFR, epidermal growth factor 
receptor; CI, confidential interval.
Fig. 4. Overall survival curves according to pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1). (A) 
CEA. (B) CYFRA 21-1. (C) Combinations of CEA and CYFRA 21-1 by group: a, patients with a low level of CEA and a high level of CYFRA 21-1; b, patients with 
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known EGFR mutation status (Figs. 2 and 3). 
Recently, genotype-driven therapy has been attempted. 
The mutation of EGFR and K-ras gene, and ALK rearrange-
ment are three major oncogenic alterations in NSCLC.34 Re-
sult from the recently presented clinical trial of crizotinib 
indicates that small molecule TKI targeting ALK transloca-
tion is very effective agent in ALK-positive NSCLC.35 Fur-
thermore, according to an encouraging result from BAT-
TLE trial, sorafenib may be used in NSCLC with KRAS 
mutation.36 Therefore, when we have sufficient tumor tissue 
and targeted agents, we could get genotype-driven therapies 
in NSCLC. However, the molecular marker test, such as 
EML4/ALK, B-raf or K-ras, could not be checked routine-
ly in clinical practice, especially because we do not have 
available tumor tissues. Accordingly, when the patients do 
not have sufficient tumor tissues or any other predictive 
biomarkers, EGFR TKI could be a good treatment option 
in patients with high CEA and low CYFRA 21-1.
In conclusion, pretreatment serum levels of CEA and 
CYFRA 21-1 are simple and easy to detect, and can serve 
as predictive and prognostic factors for advanced NSCLC 
patients who are being treated with EGFR TKIs, especially 
in patients with squamous cell carcinoma or patients with 
unknown EGFR mutation status.  
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